CARISOPRODOL PRIOR AUTHORIZATION REQUEST FORM



Please explain:_

OptumRx
P.O. Box 25184
Santa Ana, CA, 92799
Phone: (800) 310-6826 Fax: (866) 940-7328





Today's Date				
Note: This form must be completed by the prescribing provider.				
All sections must be completed or the request will be returned				
Patient's			of Birth / / /	
Patient's Name		Prescriber's Name		
Prescriber's IN License #		Specialty		
Prescriber's NPI#		Prescriber's Signature		
Return Fax #	-	- Return Phone #		
Check box if requesting retro-active PA			Date(s) of service requested for retro-active eligibility (if applicable):	
Note: Submit PA requests for retroactive claims (dates of service prior to eligibility determination, but within established eligibility timelines) with dates of service prior to 30 calendar days of submission separately from current PA requests (dates of service 30 calendar days or less and going forward).				
Requested Medication	Quantity		Dosage Regimen	
Note: Dose may not exceed 4 tablets per day of either 250 mg carisoprodol or 350 mg carisoprodol; approvals will be granted for up to 21 days' supply, to be used within a 90-day period, every 180 days PA Requirements for SOMA/VANADOM (CARISOPRODOL)				
Member has an ACUTE musculoskeletal condition diagnosed within the past 60 days □ Yes □ No				
Member is between 16 and 65 years of age \square Yes \square No				
Member is currently utilizing meproba ☐ Yes ☐ No	amate or has a hist	ory of r	neprobamate use in the last 90 days	
Member is currently utilizing opioid therapy $\ \square$ Yes $\ \square$ No				
Member is currently utilizing benzodi	azepine therapy	Yes	□ No	
Please choose one of the following: Member has a history of each	n of the preferred no	on-liqui	d oral agents	
Drug/dose/date(s) of use:				
☐ Member has documented history of intolerance to ALL the preferred non-liquid oral agents				
Please explain:	atification for the	o of a=	ricentedel ever preferred per liquid eral egents	
\square Member has valid medical justification for the use of carisoprodol over preferred non-liquid oral agents				

07.01.2023 Page 1

CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.

Page 2 07.01.2023